Market Closed -
Nasdaq
04:00:00 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
3.93
USD
|
+1.81%
|
|
-3.68%
|
-23.54%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
54.55
|
21.65
|
305.3
|
256.1
|
27.35
|
104.3
|
-
|
-
|
Enterprise Value (EV)
1 |
54.55
|
21.65
|
305.3
|
256.1
|
27.35
|
-9.783
|
43.72
|
104.3
|
P/E ratio
|
-1.42
x
|
-0.88
x
|
-4.35
x
|
-4.96
x
|
-0.44
x
|
-2.46
x
|
-2.01
x
|
-2.54
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
280
x
|
231
x
|
-120
x
|
97.8
x
|
522
x
|
-
|
EV / Revenue
|
-
|
-
|
280
x
|
231
x
|
-120
x
|
-9.17
x
|
219
x
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
0.34
x
|
-0.82
x
|
-1.53
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
296%
|
-121%
|
-65.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,421
|
1,640
|
4,778
|
6,884
|
7,311
|
27,025
|
-
|
-
|
Reference price
2 |
38.40
|
13.20
|
63.90
|
37.20
|
3.741
|
3.930
|
3.930
|
3.930
|
Announcement Date
|
6/25/19
|
6/29/20
|
6/29/21
|
6/23/22
|
6/28/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1.09
|
1.109
|
-0.2273
|
1.067
|
0.2
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.56
|
-20.8
|
-17.93
|
-47.78
|
-59.27
|
-32.36
|
-62.12
|
-65.49
|
Operating Margin
|
-
|
-
|
-1,646.06%
|
-4,308.68%
|
26,074.79%
|
-3,033.23%
|
-31,060.84%
|
-
|
Earnings before Tax (EBT)
1 |
-24.59
|
-20.77
|
-17.93
|
-47.76
|
-59.24
|
-30.09
|
-61.79
|
-65.09
|
Net income
1 |
-25.73
|
-22.04
|
-42.32
|
-48.71
|
-59.25
|
-30.09
|
-61.79
|
-65.09
|
Net margin
|
-
|
-
|
-3,884.33%
|
-4,392.42%
|
26,065.86%
|
-2,820.44%
|
-30,894.16%
|
-
|
EPS
2 |
-27.00
|
-15.00
|
-14.70
|
-7.500
|
-8.510
|
-1.598
|
-1.958
|
-1.550
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-29
|
-53
|
-68
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-2,718.54%
|
-26,500%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/25/19
|
6/29/20
|
6/29/21
|
6/23/22
|
6/28/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
0.358
|
0.3579
|
0.0389
|
0.3101
|
-0.8925
|
0.1796
|
0.1756
|
0.1776
|
0.2777
|
0.4114
|
0.2028
|
0.4
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.8
|
-10.54
|
-16.69
|
-19.77
|
-17.49
|
-9.766
|
-12.24
|
-6.998
|
-6.78
|
-7.884
|
-10.7
|
-11.2
|
-15.8
|
-18.2
|
-19.4
|
Operating Margin
|
-3,575.28%
|
-2,945.01%
|
-42,912.6%
|
-6,376.36%
|
1,959.59%
|
-5,437.92%
|
-6,969.87%
|
-3,940.2%
|
-2,441.56%
|
-1,916.38%
|
-5,277.93%
|
-2,800%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-12.79
|
-10.54
|
-16.69
|
-19.77
|
-17.48
|
-9.761
|
-12.23
|
-6.901
|
-6.588
|
-6.35
|
-10.24
|
-11
|
-15.5
|
-17.9
|
-19.2
|
Net income
1 |
-13.17
|
-10.74
|
-16.69
|
-19.78
|
-17.48
|
-9.761
|
-12.23
|
-6.903
|
-6.588
|
-6.35
|
-10.24
|
-11
|
-15.5
|
-17.9
|
-19.2
|
Net margin
|
-3,678.66%
|
-3,001.73%
|
-42,900.77%
|
-6,377.39%
|
1,958.9%
|
-5,434.97%
|
-6,962.98%
|
-3,886.88%
|
-2,372.24%
|
-1,543.46%
|
-5,051.79%
|
-2,750%
|
-
|
-
|
-
|
EPS
2 |
-2.100
|
-1.500
|
-2.700
|
-3.000
|
-2.400
|
-1.500
|
-0.8433
|
-0.9400
|
-0.6600
|
-0.2200
|
-0.3625
|
-0.3700
|
-0.4900
|
-0.5600
|
-0.6350
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
2/10/22
|
6/23/22
|
8/11/22
|
11/10/22
|
2/7/23
|
6/28/23
|
8/10/23
|
11/9/23
|
2/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
114
|
60.6
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-
|
-29
|
-53
|
-68
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.17
|
-
|
0.28
|
-
|
-
|
0.5
|
0.45
|
0.2
|
Capex / Sales
|
-
|
-
|
25.28%
|
-
|
-
|
46.87%
|
225%
|
-
|
Announcement Date
|
6/25/19
|
6/29/20
|
6/29/21
|
6/23/22
|
6/28/23
|
-
|
-
|
-
|
Last Close Price
3.93
USD Average target price
13.25
USD Spread / Average Target +237.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.54% | 104M | | +15.55% | 118B | | +12.66% | 106B | | -2.53% | 24.28B | | +1.14% | 21.96B | | -9.35% | 18.16B | | -42.28% | 16.37B | | -18.92% | 15.56B | | +6.19% | 13.63B | | +28.83% | 12.27B |
Bio Therapeutic Drugs
|